comparemela.com
Latest Breaking News On - Dellphi 301 study - Page 1 : comparemela.com
Tarlatamab Demonstrates Antitumor Activity With Durable Responses in Previously Treated SCLC
Treatment with the bispecific T-cell engager tarlatamab demonstrated antitumor activity and favorable safety outcomes in patients with previously treated small cell lung cancer.
Spain
Madrid
Luniversidad-complutense
Luis-paz
European-society-for-medical-oncology-congress
European-society
Medical-oncology-congress
Hospital-doce-de-octubre
New-england-journal
Tarlatamab
Atients-with-previously-treated-small-cell-lung-cancer
Dellphi-301-study
vimarsana © 2020. All Rights Reserved.